Funda Meric-Bernstam

Company: The University of Texas MD Anderson Cancer Center

Job title: Chair of Department of Investigational Cancer Therapeutics, Division of Cancer Medicine

Seminars:

Rethinking Patient Selection for Addressing Unique Toxicity Challenges From ADC Therapy – Balancing Risk & Access 1:02 pm

Current ADC trials often exclude high-risk patients due to concerns about toxicity, but is this the best approach? This session will explore how we can better predict, manage, and personalize ADC-related toxicities rather than defaulting to exclusion. Join this workshop to discuss topics such as: Who is at higher risk of ADC toxicity? Understanding the…Read more

day: Pre-Conference Workshop Day